Get the Stockscreener App
7.00
0.14%
0.010
After Hours:
7.00
Fulcrum Therapeutics Inc stock is traded at $7.00, with a volume of 349.59K.
It is up +0.14% in the last 24 hours and up +7.03% over the past month.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.
See More
Previous Close:
$6.99
Open:
$6.97
24h Volume:
349.59K
Relative Volume:
0.54
Market Cap:
$378.64M
Revenue:
$2.81M
Net Income/Loss:
$-97.34M
P/E Ratio:
-4.4304
EPS:
-1.58
Net Cash Flow:
$-91.47M
1W Performance:
-8.62%
1M Performance:
+7.03%
6M Performance:
+131.02%
1Y Performance:
+103.49%
1-Day Range:
$6.74
$7.06
1-Week Range:
$6.74
$7.68
52-Week Range:
$2.315
$8.50
Fulcrum Therapeutics Inc Stock (FULC) Company Profile
Name
Fulcrum Therapeutics Inc
Sector
Industry
Phone
617-651-8851
Address
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Compare FULC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FULC
Fulcrum Therapeutics Inc
|
7.00 | 378.10M | 2.81M | -97.34M | -91.47M | -1.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Fulcrum Therapeutics Inc Stock (FULC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-29-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-23-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| May-15-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Sep-13-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-12-24 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-12-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Sep-12-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Sep-12-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-12-24 | Downgrade | Stifel | Buy → Hold |
| Sep-09-24 | Upgrade | BofA Securities | Underperform → Neutral |
| May-20-24 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-13-24 | Initiated | RBC Capital Mkts | Outperform |
| Sep-25-23 | Initiated | Goldman | Neutral |
| Aug-23-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Aug-22-23 | Upgrade | Stifel | Hold → Buy |
| May-04-23 | Downgrade | Goldman | Buy → Neutral |
| Mar-10-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| Mar-10-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-09-23 | Downgrade | Stifel | Buy → Hold |
| Feb-28-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-24-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Nov-15-22 | Initiated | Goldman | Buy |
| Mar-08-22 | Initiated | Oppenheimer | Outperform |
| Mar-03-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-11-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Mar-22-21 | Initiated | Credit Suisse | Outperform |
| Mar-02-21 | Initiated | Stifel | Buy |
| Oct-16-20 | Initiated | Piper Sandler | Overweight |
| Aug-12-20 | Downgrade | BofA Securities | Neutral → Underperform |
| Aug-12-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-12-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-19-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| Oct-03-19 | Initiated | H.C. Wainwright | Buy |
| Aug-12-19 | Initiated | BofA/Merrill | Buy |
View All
Fulcrum Therapeutics Inc Stock (FULC) Latest News
Institutional scanner results for Fulcrum Therapeutics Inc.Market Growth Summary & Stepwise Trade Execution Plans - Newser
Is Fulcrum Therapeutics Inc. reversing from oversold territoryJuly 2025 Sector Moves & Weekly Chart Analysis and Trade Guides - Newser
Invesco Ltd. Acquires 55,791 Shares of Fulcrum Therapeutics, Inc. $FULC - MarketBeat
Short interest data insights for Fulcrum Therapeutics Inc.Insider Buying & Technical Confirmation Trade Alerts - Newser
Fulcrum Therapeutics Inc. stock retracement – recovery analysisJuly 2025 Analyst Calls & Safe Capital Allocation Plans - Newser
Top chart patterns to watch in Fulcrum Therapeutics Inc.Market Movers & Low Drawdown Momentum Trade Ideas - Newser
Will a bounce in Fulcrum Therapeutics Inc. offer an exitTrade Exit Summary & Risk Controlled Stock Alerts - Newser
What’s next for Fulcrum Therapeutics Inc. stock priceJuly 2025 PostEarnings & Community Consensus Trade Alerts - Newser
Real time breakdown of Fulcrum Therapeutics Inc. stock performanceTrade Signal Summary & Entry Point Strategy Guides - Newser
Fulcrum Therapeutics reports inducement grants under Nasdaq listing rule 5635(c)(4) - MarketScreener
How to use Fibonacci retracement on Fulcrum Therapeutics Inc.July 2025 PreEarnings & Weekly Breakout Opportunity Watchlist - Newser
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
35,000 Stock Options at $7.27: Fulcrum Therapeutics Awards New Employee Compensation Package - Stock Titan
Custom watchlist performance reports with Fulcrum Therapeutics Inc.2025 Pullback Review & Long Hold Capital Preservation Tips - Newser
Using Ichimoku Cloud for Fulcrum Therapeutics Inc. technicalsWeekly Trading Summary & Free Expert Approved Momentum Trade Ideas - Newser
Analyzing recovery setups for Fulcrum Therapeutics Inc. investorsStop Loss & Daily Stock Trend Reports - Newser
Will Fulcrum Therapeutics Inc. benefit from macro trendsWeekly Gains Report & Safe Capital Growth Trade Ideas - Newser
What institutional flow reveals about Fulcrum Therapeutics Inc.July 2025 Pullbacks & Daily Stock Trend Watchlist - Newser
Is this a good reentry point in Fulcrum Therapeutics Inc.2025 Trading Recap & Weekly Watchlist for Hot Stocks - Newser
Is Fulcrum Therapeutics Inc. stock entering bullish territoryJuly 2025 Short Interest & Proven Capital Preservation Methods - Newser
Fulcrum Therapeutics Inc. stock prediction for this weekIndex Update & Safe Entry Zone Tips - Newser
Market reaction to Fulcrum Therapeutics Inc.’s recent newsJuly 2025 Technicals & Technical Pattern Alert System - Newser
Combining machine learning predictions for Fulcrum Therapeutics Inc.Market Volume Report & Daily Entry Point Trade Alerts - Newser
Strategies to average down on Fulcrum Therapeutics Inc.July 2025 Technicals & Verified Entry Point Signals - Newser
How sentiment analysis helps forecast Fulcrum Therapeutics Inc.Gold Moves & Fast Entry Momentum Trade Alerts - Newser
Fulcrum Therapeutics Inc. stock daily chart insightsJuly 2025 Setups & Weekly High Return Forecasts - Newser
Using Bollinger Bands to evaluate Fulcrum Therapeutics Inc.Quarterly Earnings Report & Consistent Profit Trading Strategies - Newser
Has Fulcrum Therapeutics Inc. formed a bullish divergence2025 Biggest Moves & Long-Term Investment Growth Plans - Newser
Is Fulcrum Therapeutics Inc. stock reversal real or fakeJuly 2025 Rallies & AI Powered Market Entry Strategies - Newser
Exome Asset Management LLC Boosts Holdings in Fulcrum Therapeutics, Inc. $FULC - MarketBeat
Advanced analytics toolkit walkthrough for Fulcrum Therapeutics Inc.2025 Risk Factors & Free Low Drawdown Momentum Trade Ideas - Newser
Will Fulcrum Therapeutics Inc. rebound enough to break evenRisk Management & Free High Accuracy Swing Entry Alerts - Newser
Nuveen LLC Takes $441,000 Position in Fulcrum Therapeutics, Inc. $FULC - MarketBeat
Will breakout in Fulcrum Therapeutics Inc. lead to full recoveryPortfolio Risk Summary & Community Driven Trade Alerts - Newser
Fulcrum Therapeutics Inc Stock (FULC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):